Loading…
Based on limited metadata, this warning letter from the FDA issued on October 3, 2018, concerns Hanlim Pharm Co., Ltd., a pharmaceutical manufacturer. While the specific violations are not detailed in the available metadata, the letter addresses drug product regulatory compliance issues. The warning falls under FDA's drug product oversight, though the specific therapeutic area or manufacturing deficiency cannot be determined without access to the full letter text.